TITLE:
“Qingfei Paidu Decoction”—A Possible Choice of Phytotherapy for Severe Acute Respiratory Infection Caused by Coronavirus Disease-19
AUTHORS:
Hualiang Chen, Dandan Song, Tianlai Gao, Jingjing Yang, Yutao Ma, Qian Deng
KEYWORDS:
Qingfei Paidu Decoction, COVID-19, COPD, Pharmacology, Therapeutics
JOURNAL NAME:
American Journal of Plant Sciences,
Vol.11 No.7,
July
24,
2020
ABSTRACT: This work is aimed to study the therapeutics and
pharmacology of the treatment of severe acute respiratory infection caused by
coronavirus disease-19 (COVID-19) with traditional Chinese medicine (TCM) “Qingfei
Paidu Decoction”. We analyze the “Diagnosis and Treatment Protocol for Novel Coronavirus
Pneumonia” (Version I to Version VII) made by China, “Clinical management of
severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected—Interim
guidance” made by World Health Organization (WHO), “Therapeutic
Guidelines: Respiratory” published by Australia, and the origin of classical
prescription of Qingfei Paidu Decoction: “Shanghan Lun (Treatise on Febrile
Diseases)” and “Jinkui Yaolue (Synopsis of Golden Chamber)”. We search the
dictionary of traditional Chinese medicine (Version II) manually. We search
literatures from 2001 to 2020 on Wiley online library. We conduct a comparative
study on the therapeutic options and indications among Qingfei Paidu Decoction,
COVID-19 and chronic obstructive pulmonary disease (COPD). And we carry out
pharmacological inquiry of Qingfei Paidu Decoction. The therapeutic options and
indications of Qingfei Paidu Decoction in China, COVID-19 and COPD are
considered to be basically consistent. Qingfei Paidu Decoction has a definite
therapeutic effect on the symptoms, basic diseases and complications for
COVID-19 and COPD. Qingfei Paidu Decoction is a possible choice of phytotherapy for severe acute respiratory infection caused by COVID-19.